Vaccine Info

SpFN SARS-CoV-2 Vaccine

SpFN SARS-CoV Vaccine Description

SpFN was developed internally at Walter Reed Army Institute of Research (WRAIR).

The vaccine, currently called “SpFN” (short for “spike ferritin nanoparticle”) employs ferritin, a protein found in almost all living organisms.

By attaching a certain type of spike protein to a polymerized version of ferritin, WRAIR scientists hope the resulting vaccination dose will block COVID-19 infection.

SpFN SARS-CoV Vaccine Indication

SpFN SARS-CoV-2 vaccine is indicated to prevent COVID-19 disease caused by the SARS-C0V-2 vaccine.

SpFN SARS-CoV Vaccine Clinical Trials

SpFN expects to begin Phase 1 clinical trials later this year. The news was delivered during a press briefing with national media outlets on October 14.

SpFN SARS-CoV Vaccine News

October 16, 2020 - WRAIR Announces COVID-19 Vaccine Candidate, Targets Clinical Trial Date